Published in Kidney Int on June 01, 1994
Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A (2007) 2.52
Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int (2011) 2.28
The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol (2014) 1.70
DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res (2009) 1.23
The etiology of Balkan endemic nephropathy: still more questions than answers. Environ Health Perspect (1998) 1.19
Etiology of Balkan endemic nephropathy: a multifactorial disease? Eur J Epidemiol (1998) 1.04
Gene expression profiles distinguish the carcinogenic effects of aristolochic acid in target (kidney) and non-target (liver) tissues in rats. BMC Bioinformatics (2006) 1.02
Microarray platform consistency is revealed by biologically functional analysis of gene expression profiles. BMC Bioinformatics (2009) 0.98
p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy. Mutat Res (2009) 0.93
Physiological and molecular characterization of aristolochic acid transport by the kidney. J Pharmacol Exp Ther (2011) 0.92
Structure and stability of DNA containing an aristolactam II-dA lesion: implications for the NER recognition of bulky adducts. Nucleic Acids Res (2011) 0.91
Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int J Cancer (2010) 0.91
Balkan endemic nephropathy-current status and future perspectives. Clin Kidney J (2013) 0.91
A reassessment of risk associated with dietary intake of ochratoxin A based on a lifetime exposure model. Crit Rev Toxicol (2012) 0.89
Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy. Nephrol Dial Transplant (2013) 0.88
Development of a chronic kidney disease model in C57BL/6 mice with relevance to human pathology. Nephron Extra (2013) 0.88
The involvement of mycotoxins in the development of endemic nephropathy. Wien Klin Wochenschr (2008) 0.86
Complications of traditional Chinese/herbal medicines (TCM)--a guide for perplexed oncologists and other cancer caregivers. Support Care Cancer (2008) 0.84
Balkan endemic nephropathy in Vratza, Bulgaria, 1964-1987: an epidemiologic analysis of population-based disease registers. Eur J Epidemiol (2001) 0.84
Could disappearance of endemic (Balkan) nephropathy be expected in forthcoming decades? Kidney Blood Press Res (2011) 0.83
Chinese herb nephropathy. Proc (Bayl Univ Med Cent) (2000) 0.82
Chinese herbs containing aristolochic acid associated with renal failure and urothelial carcinoma: a review from epidemiologic observations to causal inference. Biomed Res Int (2014) 0.81
Unambiguous detection of multiple TP53 gene mutations in AAN-associated urothelial cancer in Belgium using laser capture microdissection. PLoS One (2014) 0.80
Tubular marker excretion in children from families with Balkan nephropathy. Pediatr Nephrol (2009) 0.80
Possible health impacts of naturally occurring uptake of aristolochic acids by maize and cucumber roots: links to the etiology of endemic (Balkan) nephropathy. Environ Geochem Health (2012) 0.80
An Integrated View of Aristolochic Acid Nephropathy: Update of the Literature. Int J Mol Sci (2017) 0.79
Tubulointerstitial nephritis: diagnosis, treatment, and monitoring. Pediatr Nephrol (2016) 0.79
Why are upper tract urothelial carcinoma two different diseases? Transl Androl Urol (2016) 0.78
Total synthesis of the aristolochic acids, their major metabolites, and related compounds. Chem Res Toxicol (2014) 0.78
Text mining of the classical medical literature for medicines that show potential in diabetic nephropathy. Evid Based Complement Alternat Med (2014) 0.78
Genetic loci that affect aristolochic acid-induced nephrotoxicity in the mouse. Am J Physiol Renal Physiol (2011) 0.77
Pro- and antiapoptotic markers in upper tract urothelial carcinoma associated with Balkan endemic nephropathy. ScientificWorldJournal (2011) 0.77
Angiogenesis in upper tract urothelial carcinoma associated with Balkan endemic nephropathy. Int J Clin Exp Pathol (2012) 0.76
Blocking TGF-β Signaling Pathway Preserves Mitochondrial Proteostasis and Reduces Early Activation of PDGFRβ+ Pericytes in Aristolochic Acid Induced Acute Kidney Injury in Wistar Male Rats. PLoS One (2016) 0.76
Sulfotransferase-1A1-dependent bioactivation of aristolochic acid I and N-hydroxyaristolactam I in human cells. Carcinogenesis (2016) 0.76
Balkan endemic nephropathy: an update on its aetiology. Arch Toxicol (2016) 0.75
Pharmacokinetics of p-Aminohippuric Acid and Inulin in Rabbits with Aristolochic Acid Nephropathy. Adv Pharmacol Sci (2011) 0.75
Upper urothelium carcinomas in Croatian endemic area. Wien Klin Wochenschr (2013) 0.75
Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int (2007) 7.75
Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet (1993) 6.56
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med (1999) 2.33
A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation (1999) 2.27
Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis (1999) 2.05
Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation (1997) 1.90
Comparative potency of atenolol and propranolol as beta-adrenergic blocking agents in man. Eur J Clin Pharmacol (1976) 1.80
IMx tacrolimus II vs IMx tacrolimus microparticle enzyme immunoassay evaluated in renal and hepatic transplant patients. Clin Chem (1997) 1.67
Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int (2007) 1.66
Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect. Int J Clin Pharmacol Ther Toxicol (1982) 1.65
Thrombotic microangiopathy induced by long-term interferon-β therapy for multiple sclerosis: a case report. Clin Nephrol (2011) 1.64
Aristolochic acid nephropathy in a Chinese patient: time to abandon the term "Chinese herbs nephropathy"? Am J Kidney Dis (2001) 1.61
Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferon-alpha 2b. Nephrol Dial Transplant (1995) 1.59
Safe preservation of human renal cadaver transplants by Euro-Collins solution up to 50 hours. Transplant Proc (1981) 1.50
Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int (1999) 1.46
Antineutrophil cytoplasmic autoantibodies in atheroembolic disease. Nephrol Dial Transplant (1998) 1.45
Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? Kidney Int (2001) 1.43
The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther (1998) 1.42
Splenic lymphoma presenting as necrotizing glomerulonephritis. Clin Nephrol (1998) 1.39
Bone mass evolution after renal transplantation. Kidney Int (2001) 1.38
No association between Alport's syndrome and antithyroid antibodies. Nephrol Dial Transplant (1992) 1.38
Technetium-99m L,L-ethylenedicysteine clearance and correlation with iodine-125 orthoiodohippurate for the determination of effective renal plasma flow. Eur J Nucl Med (1996) 1.37
Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc (1987) 1.35
Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation (2000) 1.33
Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int (1998) 1.32
Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res (1996) 1.28
Effect of intrauterine growth retardation on the clinical course and prognosis of IgA glomerulonephritis in children. Nephron (1998) 1.26
Possible role of dialysis membrane characteristics in amyloid osteoarthropathy. Lancet (1986) 1.20
Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int (1997) 1.18
Histological characteristics of sternoclavicular beta 2-microglobulin amyloidosis and clues for its histogenesis. Kidney Int (1999) 1.17
Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int (1991) 1.16
An outbreak of Ochrobactrum anthropi bacteraemia in five organ transplant patients. J Hosp Infect (1994) 1.16
Laboratory rat associated outbreak of haemorrhagic fever with renal syndrome due to Hantaan-like virus in Belgium. Lancet (1984) 1.15
Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit (2003) 1.10
Beta-2 microglobulin in renal disease. J Am Soc Nephrol (1998) 1.08
[Methodology and practical use in hemodialysis of the percentage of urea reduction (PUR)]. Nephrologie (1995) 1.08
Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation (2001) 1.08
Oral ciprofloxacin to treat bacterial peritonitis associated with peritoneal dialysis. Clin Nephrol (1997) 1.07
Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem (2001) 1.06
Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood: II. Application to rheumatoid arthritis and osteoarthritis. Cytokine (1992) 1.06
Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus (2003) 1.06
Renal side effects of nonsteroidal antiinflammatory drugs: clinical relevance. Am J Kidney Dis (1986) 1.06
Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int (1993) 1.05
32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis (1997) 1.05
The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation (1994) 1.03
Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol (1998) 1.02
Sixteen novel mutations identified in COL4A3, COL4A4, and COL4A5 genes in Slovenian families with Alport syndrome and benign familial hematuria. Kidney Int (2007) 1.02
Outcome of patients with tuberous sclerosis after renal transplantation. Transplantation (1990) 1.02
Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol (1996) 1.02
Relationship between blood level of atenolol and pharmacologic effect. Clin Pharmacol Ther (1977) 1.01
Combined immunosuppressive therapy with cyclosporin A and azathioprine. A synergistic effect in three of four experimental models. Transplantation (1982) 1.01
Low molecular weight proteinuria in human immunodeficiency virus-infected patients. Am J Kidney Dis (1996) 1.00
Bee stings and acute tubular necrosis. Nephron (1982) 0.99
Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. Kidney Int (1997) 0.98
Video-assisted neck exploration for primary and secondary hyperparathyroidism: initial experience. Surg Endosc (2001) 0.98
Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. Kidney Int (2001) 0.98
Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int (1998) 0.97
Unfavorable course of minimal change nephrotic syndrome in children with intrauterine growth retardation. Kidney Int (1998) 0.97
Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int (1994) 0.97
The relationship between beta-blockade, hyporeninaemic and hypotensive effect of two beta-blocking agents. Postgrad Med J (1976) 0.97
Adult porcine islet transplantation in baboons treated with conventional immunosuppression or a non-myeloablative regimen and CD154 blockade. Xenotransplantation (2002) 0.96
Multiple spontaneous ruptures of tendons in renal transplant recipient. Br Med J (Clin Res Ed) (1984) 0.96
Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int Suppl (2000) 0.96
Captopril-induced acute reversible renal failure. Nephron (1983) 0.96
Low molecular weight proteinuria in Chinese herbs nephropathy. Kidney Int (1995) 0.95
Course of Henoch-Schönlein nephritis after renal transplantation. Report on ten patients and review of the literature. Transplantation (1994) 0.94
Hemolytic uremic syndrome in three adult siblings: a familial study and evolution. Clin Nephrol (1987) 0.94
Urothelial malignancy in nephropathy due to Chinese herbs. Lancet (1994) 0.94
Increase of physical activity level after successful renal transplantation: a 5 year follow-up study. Nephrol Dial Transplant (2001) 0.94
Hypertension after renal transplantation. Br Med J (1976) 0.94
Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem (2001) 0.94
Human ABO-incompatible living donor renal homografts. Neth J Med (1985) 0.92
Factors influencing serum levels and peritoneal clearances of low molecular weight proteins in continuous ambulatory peritoneal dialysis. Kidney Int (1995) 0.91
Large vessel vasculitis without temporal artery involvement: isolated form of giant cell arteritis? Clin Rheumatol (1996) 0.91
Real-time ultrasound-guided renal biopsy with a biopsy gun in children: safety and efficacy. Acta Paediatr (2001) 0.91
Complications of autosomal dominant polycystic kidney disease in 50 haemodialysed patients. A case-control study. The U.C.L. Collaborative Group. Nephrol Dial Transplant (1996) 0.90
Recurrence of membranous nephropathy after renal transplantation: probability, outcome and risk factors. Clin Nephrol (1998) 0.90
Hypercalcaemic phaeochromocytoma. Br Med J (1976) 0.90
Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int (1998) 0.90
Pancreas transplantation for treatment of generalized allergy to human insulin in type 1 diabetes. Transplant Proc (2005) 0.89
Contribution to the pathogenesis of radiation-induced injury to large arteries. J Laryngol Otol (1997) 0.89
Acute colonic complications after kidney transplantation. Acta Chir Belg (1995) 0.89
Norfloxacin and cyclosporine--a safe combination. Transplantation (1989) 0.89
Contributions of the video-assisted approach to thyroid and parathyroid surgery. Acta Chir Belg (2002) 0.89
ANCA-positive rapidly progressive glomerulonephritis: there may be more to the diagnosis than you think! Nephrol Dial Transplant (1997) 0.88